Long-term follow-up of patients with aplastic anemia and refractory anemia responding to combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin.
In our previous study, approximately 60% of aplastic anemia (AA) and refractory anemia (RA) patients treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human erythropoietin (rhEpo) showed a multilineage response. In this study, we analyzed the long-term follow-up of the multilineage responders (multi-R). In the follow-up analysis of 11 multi-R (6 AA and 5 RA), 10 patients (5 AA and 5 RA) were evaluable. The range of time from the start of treatment to the final contact was 50 to 125 months. Analysis of survival times revealed a significant difference between multi-R and non-multi-R among AA patients given this treatment (P = .016). One AA and 1 RA patient among the multi-R developed acute leukemia. Of 7 living multi-R, 3 AA and 2 RA patients did not need transfusion at final contact. Four of them maintained the target hemoglobin concentration of more than 11 g/dL for quality-of-life benefit. The findings suggested that this result is an important advantage of this treatment.
Matsuda
Akira
A
amatsu@saitama-med.ac.jp
Kishimoto
Kuniya
K
Yoshida
Katsuhiko
K
Yagasaki
Fumiharu
F
Ito
Yoshihiro
Y
Sakata
Tohru
T
Kawai
Nobutaka
N
Ino
Hirohide
H
Hirashima
Kunitake
K
Bessho
Masami
M
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000188:drug therapy* / Q000473:pathology; D000753:Anemia, Refractory / Q000188:drug therapy* / Q000473:pathology; D001803:Blood Transfusion; D004921:Erythropoietin / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis
D004921:Erythropoietin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor